Andrew Krivoshik (Astellas)
Astellas and Seagen's Padcev wins full FDA approval, notching expanded label in tough-to-crack urothelial cancer
Two years after Seagen and Astellas won a conditional FDA approval to target urothelial cancer, the pair’s Padcev drug has been given a full endorsement …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
